

November 9, 2020

Q2FY21 Result Update

☑ Change in Estimates | ☑ Target | ☑ Reco

Change in Estimates

	Cur	rent	Previous		
	FY22E	FY23E	FY22E	FY23E	
Rating	BUY		н	OLD	
Target Price	3	52	239		
Sales (Rs. m)	15,249	17,465	15,429	17,465	
% Chng.	(1.2)	-			
EBITDA (Rs. m)	2,435	2,792	2,192	2,480	
% Chng.	11.1	12.6			
EPS (Rs.)	15.7	19.6	13.3	18.1	
% Chng.	18.0	7.9			

Key Financials - Consolidated

Y/e Mar	FY20	FY21E	FY22E	FY23E
Sales (Rs. m)	10,794	12,464	15,249	17,465
EBITDA (Rs. m)	967	1,982	2,435	2,792
Margin (%)	9.0	15.9	16.0	16.0
PAT (Rs. m)	242	1,014	1,443	1,802
EPS (Rs.)	2.6	11.0	15.7	19.6
Gr. (%)	(1,249.3)	318.2	42.3	24.9
DPS (Rs.)	0.3	0.3	0.3	0.3
Yield (%)	0.1	0.1	0.1	0.1
RoE (%)	3.6	14.8	18.5	18.9
RoCE (%)	2.9	13.8	16.7	17.5
EV/Sales (x)	2.3	2.0	1.6	1.3
EV/EBITDA (x)	26.1	12.4	9.8	8.3
PE (x)	97.5	23.3	16.4	13.1
P/BV (x)	3.5	3.4	2.7	2.3

Key Data	INRM.BO INDR IN
52-W High / Low	Rs.296 / Rs.140
Sensex / Nifty	41,893 / 12,264
Market Cap	Rs.24bn/ \$ 318m
Shares Outstanding	92m
3M Avg. Daily Value	Rs.140.9m

Shareholding Pattern (%)

Promoter's	58.69
Foreign	2.22
Domestic Institution	14.67
Public & Others	24.42
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(1.4)	11.6	65.9
Relative	(6.9)	(15.6)	60.2

Surajit Pal

surajitpal@plindia.com | 91-22-66322259

Tausif Shaikh

tausifshaikh@plindia.com | 91-22-66322246

Indoco Remedies (INDR IN)

Rating: BUY | CMP: Rs256 | TP: Rs352

Signs of earnings recovery : Upgrade to BUY

Quick Pointers:

- Guided US revenue of Rs1.5bn (vs. Rs560m in FY20) for FY21E and Rs2.5bn for FY22E with domestic formulation of 10-12% growth.
- Return ratios, headline margins to expand with more US contributions.

We incorporate INDR's guidance in our assumption and upgrade to Buy (earlier Hold) led by increase in earnings estimate by 14%/18%/8% for FY21/22/23E mainly due to EBITDAM expansion of 200-300bps.INDR guided for 1) increased MR productivity with same number of field force, 2) US launch of ophthalmic and oral ANDAs in partnerships and 3) lower remediation cost as regulatory issue are resolved. INDR earnings were in line with our estimate, led by growth in export formulation while India formulations suffered due to lockdown and lower demand for acute products (55% of India revenue). We believe, over the last few years INDR was in CAPEX mode and growth suffered due to regulatory issues. With guidance of limited CAPEX, regulatory issues resolved and restructured sales force, INDR is poised to grow on better contributions from two key markets, US and India.We roll over our valuation to FY23E (from FY22E) and derive at new TP of Rs352 (earlier Rs239) based on 18x (unchanged) PE of FY23E EPS of Rs20. We upgrade our rating to Buy (earlier Hold).

Export market drives growth: Revenue grew 13% YoY and 21%QoQ to Rs3.2bn (PLe: Rs3.0bn) led by growth in export formulation of 64% YoY and 27% QoQ. EBITDA grew 113% YoY and 38% QoQ to Rs550mn (PLe: Rs477mn) while EBITDA Margin was 17.1% (PLe: 15.6%) versus 9% YoY and 15% QoQ. PBT was Rs362m (PLe: Rs312m) v/s Rs33m YoY and Rs242m QoQ. While PAT was Rs251m (PLe: Rs250m) v/s Rs73m YoY and Rs172m QoQ.

Conference Call Highlights

- India formulations: Domestic formulations declined 6% YoY making it second consecutive declining quarter due to lockdown. INDR gave a strong guidance for 2HFY21 as marketing activities are reaching at pre-COVID levels and 4QFY21 would capture some part of seasonality benefit for channel filling of acute products. INDR guided domestic formulation growth of 10-12% from FY22E onwards with more focus on chronic product, higher revenue contribution from eastern India and increase in MR productivity. INDR launched FEVINDO 400 (Favipiravir) in India while Apixabid (Apixaban) launched in December'19 and later is was withdrawn due to ad-interim injunction. The injunction order is further delayed with no guidance on litigation outcome. Legacy product (more than 3 years old) contributes 55-60% to domestic business. It has 2,300 MRs with most of them still remaining off the field.
- US market: Revenue grew 62% QoQ to Rs434mn. It received approval for Olanzapine tabs in 1QFY21 and plans to launch in 2HFY21E. During the quarter, company dispatched four products to USA for launch by partners. The products include 3 injectables viz., Phenylephrine, Palonosetron, Zoledronic

acid and one solid dosage viz., Febuxostat tablet. The Company received repeat orders for the products shipped in 1QFY21. Guided revenue of Rs1.5bn (vs. Rs560m in FY20) for FY21E and Rs2.5bn for FY22E.

- Europe and EMs: Europe revenue grew 32% QoQ and guided Rs2.2bn for FY21E alongside 15-20% growth for FY22. INDR is a contract manufacture for paracetamol in Europe while EM grew 6% QoQ.
- API: Grew 3%% QoQ to Rs228m in 2QFY21. Guided for 20% growth in FY21E.
- CAPEX/ R&D/ Debt: CAPEX was Rs500m for FY20 and guided similar range for FY21E. INDR has a gross debt of Rs2.6bn with long and short term borrowing at Rs1.45bn and 1.3bn.

Exhibit 1: 2QFY21 Result Overview (Rs m): Export formulation drives growth

Y/e March	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	H1FY21	H1FY20	YoY gr. (%)
Net Sales	3,225	2,856	12.9	2,668	5,893	5,328	10.6
Raw Material	902	896	0.7	816	1,718	1,752	(1.9)
% of Net Sales	28.0	31.4		30.6	29.2	32.9	
Personnel Cost	749	639	17.2	656	1,404	1,245	12.8
% of Net Sales	23.2	22.4		24.6	23.8	23.4	
Others	1,024	1,064	(3.7)	798	1,822	1,901	(4.1)
% of Net Sales	31.8	37.2		29.9	30.9	35.7	
Total Expenditure	2,675	2,598	2.9	2,270	4,945	4,898	1.0
EBITDA	550	258	113.4	398	948	430	120.3
Margin (%)	17.1	9.0		14.9	16.1	8.1	
Depreciation	186	180	2.9	191	377	350	7.6
EBIT	364	77	371.2	207	571	80	613.6
Other Income	57	70	(17.8)	93	150	131	14.9
Interest	59	54	9.7	58	116	115	1.3
PBT	362	93	289.3	242	605	96	530.7
Extra-Ord. Inc./Exps.	-	-		-	-	-	
Total Taxes	111	20	462.1	70	181	-	NA
ETR (%)	30.7	21.3		28.9	30.0	0.5	
Reported PAT	251	73	242.6	172	423	95	343.5

Source: Company, PL

P

Exhibit 2: Major Sources of Revenues

Major sources of revenues	Q2FY21	Q2FY20	YoY gr. (%)	Q1FY21	H1FY21	H1FY20	YoY gr. (%)
Domestic	1,841	1,926	(4.4)	1,559	3,521	3,628	(3.0)
Formulations	1,747	1,863	(6.2)	1,475	3,384	3,479	(2.7)
APIs	94	63	50.1	84	137	149	(8.1)
Exports	1,348	913	47.7	1,093	1,880	1,657	13.5
Formulations	1,213	741	63.7	955	1,627	1,335	21.9
Reg mkt	1,013	516	96.2	765	1,227	948	29.3
Non-reg mkt (Emerging mkt)	200	225	(11.0)	190	401	386	3.7
APIs	134	171	(21.4)	138	252	322	(21.6)
Net Sales	3,189	2,838	12.4	2,652	5,400	5,284	2.2
Add: CRO	35	18		17	35	35	
Net Revenues	3,224	2,856	12.9	2,668	5,436	5,320	2.2

Source: Company, PL





Exhibit 3: Domestic formulations: Growth muted due to lockdown


Source: Company, PL

Exhibit 4: Export: Regulated Mkt : Current growth driven by export market



Source: Company, PL

Exhibit 5: Export, Semi-Reg. mkt sales



Source: Company, PL





Exhibit 6: API sales and growth

Source: Company, PL





Source: Company, PL

Indoco Remedies

FY22E

12,312

FY23E

12,862

Financials

Income Statement (Rs m)

								_
Y/e Mar	FY20	FY21E	FY22E	FY23E	Y/e Mar	FY20	FY21E	
Net Revenues	10,794	12,464	15,249	17,465	Non-Current Assets			
YoY gr. (%)	14.6	15.5	22.3	14.5				
Cost of Goods Sold	3,304	3,530	4,102	4,688	Gross Block	11,212	11,712	1
Gross Profit	7,490	8,934	11,146	12,777	Tangibles	8,953	9,303	
Margin (%)	69.4	71.7	73.1	73.2	Intangibles	2,259	2,409	
Employee Cost	2,553	2,914	3,348	3,842				
Other Expenses	497	588	743	851	Acc: Dep / Amortization	5,369	6,611	
					Tangibles	3,590	4,419	
EBITDA	967	1,982	2,435	2,792	Intangibles	1,779	2,192	
YoY gr. (%)	92.3	104.9	22.8	14.7				
Margin (%)	9.0	15.9	16.0	16.0	Net fixed assets	5,844	5,101	
					Tangibles	5,364	4,884	
Depreciation and Amortization	708	748	787	786	Intangibles	480	217	
EBIT	259	1,234	1,648	2,006	Capital Work In Progress	560	631	
Margin (%)	2.4	9.9	10.8	11.5	Goodwill	1	1	
					Non-Current Investments	69	77	
Net Interest	263	180	135	87	Net Deferred tax assets	359	420	
Other Income	290	265	289	332	Other Non-Current Assets	252	303	
Profit Before Tax	287	1,320	1,803	2,251	Current Assets			
Margin (%)	2.7	10.6	11.8	12.9	Investments	-	-	
5 (14)					Inventories	2,083	2,288	
Total Tax	45	305	359	449	Trade receivables	2,101	2,629	
Effective tax rate (%)	15.5	23.1	19.9	19.9	Cash & Bank Balance	379	1,162	
					Other Current Assets	1,026	872	
Profit after tax	242	1,014	1,443	1,802	Total Assets	12,716	13,534	1
Minority interest	-	-	-	-				
Share Profit from Associate	-	-	-	-	Equity			
					Equity Share Capital	184	184	
Adjusted PAT	242	1,014	1,443	1,802	Other Equity	6,611	6,761	
YoY gr. (%)	(1,249.3)	318.2	42.3	24.9	Total Networth	6,796	6,946	
Margin (%)	2.2	8.1	9.5	10.3				
Extra Ord. Income / (Exp)	-	-	-	-	Non-Current Liabilities			
					Long Term borrowings	969	872	
Reported PAT	242	1,014	1,443	1,802	Provisions	233	198	
YoY gr. (%)	(1,249.3)	318.2	42.3	24.9	Other non current liabilities	-	-	
Margin (%)	2.2	8.1	9.5	10.3				
					Current Liabilities			
Other Comprehensive Income	-	-	-	-	ST Debt / Current of LT Debt	1,060	1,272	
Total Comprehensive Income	242	1,014	1,443	1,802	Trade payables	1,656	2,083	
Equity Shares O/s (m)	92	92	92	92	Other current liabilities	1,874	2,061	
EPS (Rs)	2.6	11.0	15.7	19.6	Total Equity & Liabilities	12,716	13,535	_1

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

		,		,
Tangibles	8,953	9,303	9,603	9,853
Intangibles	2,259	2,409	2,709	3,009
cc: Dep / Amortization	5,369	6,611	7,390	7,793
Tangibles	3,590	4,419	4,898	5,025
Intangibles	1,779	2,192	2,492	2,768
let fixed assets	5,844	5,101	4,922	5,069
Tangibles	5,364	4,884	4,706	4,828
Intangibles	480	217	217	241
capital Work In Progress	560	631	673	727
Goodwill	1	1	1	1
Ion-Current Investments	69	77	85	93
let Deferred tax assets	359	420	492	582
Other Non-Current Assets	252	303	352	410
Current Assets				
Investments	-	-	-	-
Inventories	2,083	2,288	2,757	3,158
Trade receivables	2,101	2,629	3,008	3,445
Cash & Bank Balance	379	1,162	1,827	2,271
Other Current Assets	1,026	872	741	630
otal Assets	12,716	13,534	14,932	16,488
quity				
Equity Share Capital	184	184	184	184
Other Equity	6,611	6,761	8,448	10,211
otal Networth	6,796	6,946	8,632	10,395
Ion-Current Liabilities				
Long Term borrowings	969	872	785	707
Provisions	233	198	168	143
Other non current liabilities	-	-	-	-
urrent Liabilities				
ST Debt / Current of LT Debt	1,060	1,272	1,208	1,148
Trade payables	1,656	2,083	2,548	2,919
Other current liabilities	1,874	2,061	1,498	1,093
otal Equity & Liabilities	12,716	13,535	14,932	16,488

Source: Company Data, PL Research

P

Cash Flow (Rs m)

Y/e Mar	FY20	FY21E	FY22E	FY23E
PBT	287	1,320	1,803	2,251
Add. Depreciation	708	748	787	786
Add. Interest	263	180	135	87
Less Financial Other Income	290	265	289	332
Add. Other	38	1,268	(273)	(820)
Op. profit before WC changes	1,295	3,516	2,452	2,304
Net Changes-WC	(443)	(306)	(383)	(467)
Direct tax	(69)	(317)	(433)	(540)
Net cash from Op. activities	784	2,893	1,636	1,296
Capital expenditures	(1,867)	(500)	(600)	(550)
Interest / Dividend Income	19	19	19	19
Others	-	(2)	-	-
Net Cash from Invt. activities	(1,848)	(483)	(581)	(531)
Issue of share cap. / premium	-	-	-	-
Debt changes	(445)	130	(198)	(179)
Dividend paid	(39)	(39)	(39)	(39)
Interest paid	(263)	(180)	(135)	(87)
Others	-	-	-	-
Net cash from Fin. activities	(746)	(88)	(372)	(305)
Net change in cash	(1,810)	2,322	683	460
Free Cash Flow	(1,083)	2,393	1,036	746
Source: Company Data, PL Resear	rch			

Quarterly Financials (Rs m)

Y/e Mar	Q3FY20	Q4FY20	Q1FY21	Q2FY21
Net Revenue	2,834	2,632	2,668	3,225
YoY gr. (%)	14.3	7.4	7.9	12.9
Raw Material Expenses	828	724	816	902
Gross Profit	2,006	1,908	1,852	2,323
Margin (%)	70.8	72.5	69.4	72.0
EBITDA	292	245	398	550
YoY gr. (%)	185.4	13.9	130.6	113.4
Margin (%)	10.3	9.3	14.9	17.1
Depreciation / Depletion	176	182	191	186
EBIT	116	63	207	364
Margin (%)	4.1	2.4	7.7	11.3
Net Interest	69	78	58	59
Other Income	66	93	93	57
Profit before Tax	113	78	242	362
Margin (%)	4.0	3.0	9.1	11.2
Total Tax	20	24	70	111
Effective tax rate (%)	17.6	30.8	28.9	30.7
Profit after Tax	93	54	172	251
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	93	54	172	251
YoY gr. (%)	74.2	(53.6)	677.5	242.6
Margin (%)	3.3	2.1	6.5	7.8
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	93	54	172	251
YoY gr. (%)	74.2	(53.6)	677.5	242.6
Margin (%)	3.3	2.1	6.5	7.8
Other Comprehensive Income	-	(16)	(1)	(1)
Total Comprehensive Income	93	38	171	250
Avg. Shares O/s (m)	92	92	92	92
EPS (Rs)	1.0	0.6	1.9	2.7

Y/e Mar	FY20	FY21E	FY22E	FY23E
Per Share(Rs)				
EPS	2.6	11.0	15.7	19.6
CEPS	10.3	19.1	24.2	28.1
BVPS	73.7	75.4	93.7	112.8
FCF	(11.8)	26.0	11.2	8.1
DPS	0.3	0.3	0.3	0.3
Return Ratio(%)				
RoCE	2.9	13.8	16.7	17.5
ROIC	2.6	12.2	16.4	17.5
RoE	3.6	14.8	18.5	18.9
Balance Sheet				
Net Debt : Equity (x)	0.2	0.1	0.0	0.0
Net Working Capital (Days)	86	83	77	77
Valuation(x)				
PER	97.5	23.3	16.4	13.1
P/B	3.5	3.4	2.7	2.3
P/CEPS	24.9	13.4	10.6	9.1
EV/EBITDA	26.1	12.4	9.8	8.3
EV/Sales	2.3	2.0	1.6	1.3
Dividend Yield (%)	0.1	0.1	0.1	0.1

Key Operating Metrics

Y/e Mar	FY20	FY21E	FY22E	FY23E
Domestic Formulations	6,862	7,548	8,454	9,469
Export Formulations	2,963	4,717	5,909	6,304
APIs	860	1,023	1,227	1,476


Source: Company Data, PL Research

Indoco Remedies

Indoco Remedies

Price Chart





No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	13-Oct-20	Hold	239	252
2	12-Aug-20	Hold	243	262
3	08-Jul-20	Hold	219	208
4	25-Jun-20	Hold	219	211
5	18-Apr-20	Hold	259	236
6	14-Apr-20	Reduce	198	248
7	23-Jan-20	Hold	198	234
8	03-Jan-20	Hold	157	185

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aurobindo Pharma	Hold	808	834
2	Cadila Healthcare	Sell	357	411
3	Cipla	Reduce	657	814
4	Cipla	Reduce	657	787
5	Dr. Lal PathLabs	UR	-	2,179
6	Dr. Reddy's Laboratories	BUY	5,964	4,951
7	Eris Lifesciences	BUY	671	518
8	Glenmark Pharmaceuticals	Sell	349	496
9	Indoco Remedies	Hold	239	252
10	Ipca Laboratories	Hold	1,886	2,113
11	Jubilant Life Sciences	Accumulate	752	696
12	Lupin	BUY	1,212	936
13	Sun Pharmaceutical Industries	BUY	597	486
14	Thyrocare Technologies	UR	-	1,138

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com